The combined entity will enable the company to better serve the needs of patients, healthcare professionals and customers around the world, he added. Upon completion of the merger, currently expected to close in around 35 days, Taro will become a privately held company, wholly-owned by Sun Pharma and soon after its shares will be de-listed from the NYSE.
